Interleukin-1 Receptor-Like 2 cytokine accomplishes a dual effect in inflammation and healing

The Interleukin-1 Receptor-Like 2 (IL-1RL2) cytokine can promote inflammatory diseases and have a role in controlling infection. The receptor can recognize multiple agonists and has been implicated in the development of inflammatory diseases such as psoriasis and inflammatory bowel disease (IBD). A comprehensive review of IL-1RL2 is published in the peer-reviewed Journal of Interferon & Cytokine Research (JICR).

O. Medina-Contreras, from Mexico Children's Hospital, and coauthors, review the many implications of IL-11RL-2, also known as IL-36 in the skin, lungs, and gut. They discuss its ability to promote the expression of inflammatory cytokines and chemokines and its role in infection, including a potential role in COVID-19 pathology.

"It seems that the IL-36IL-1RL2 axis has both inflammatory and healing functions, probably depending on other mediators in the extracellular milieu and the stage of the infection," state the investigators. "There is still much to discover about this recently described cytokine family, its functions in other organs, and how it accomplishes a dual effect in both inflammation and healing."

This is a fascinating review that highlights the importance of IL-36-IL-1RL2 in the development of several inflammation-related diseases and the healing process. The paper is an excellent example of the innovative and cutting-edge research published in the journal."

David L. (Woody) Woodland, PhD., Journal of Interferon & Cytokine Research Editor-in-Chief

Source:
Journal reference:

Manzanares-Meza, L.D., et al. (2022) Interleukin-1 Receptor-Like 2: One Receptor, Three Agonists, and Many Implications. Journal of Interferon & Cytokine Research. doi.org/10.1089/jir.2021.0173.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing MASLD treatment with GLP-1 receptor agonists